Bacteria building resistance to moxifloxacin

Article

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers.

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers, according to Gita Sathpathy and co-workers at the All India Institute of Medical Sciences, New Dehli, India.

The records of 934 consecutive cases of bacterial corneal ulcers were retrospectively reviewed and culture and antibiotic sensitivity reports of corneal scrapings were analysed. Recorded parameters included age, sex, organism isolated and sensitivity, using Kirby-Bauer disc-diffusion, to moxifloxacin. The bacterial isolates that were resistant to moxifloxacin were examined in detail and their antibiotic sensitivity to other drugs was studied.

Of the 934 bacterial isolates, 913 (97.5%) were sensitive to moxifloxacin and 21 (2.25%) were found to be resistant. Of the 21 resistant isolates, eight were Staphylococcus albus, eight were Pseudomonas, two were Streptococcus viridians, one was Streptococcus pneumoniae, one was Staphylococcus aureus and one was E. coli. Of the eight Pseudomonas cases, six were found to be sensitive to polymyxin and five sensitive to amikacin. Out of the eight Staphylococcus, seven were sensitive to vancomycin.

The emergence of a resistance to moxifloxacin in bacteria isolated from corneal ulcers, indicates that the drug should not be used indiscriminately.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.